Alternatively, or in addition, as it up to 35% of gastric tumors lost their HER2+ status after I line therapy, a decreased level of HER2 could impair the activity of T-DM1 but not that of taxanes. The gene discussed is ERBB2; the disease is gastric neoplasm.